THE MINISTRY OF HEALTH
THE DRUG ADMINISTRATION OF VIETNAM

Official Dispatch No. 4336/QLD-CL dated March 24, 2014 of the Drug Administration of Vietnam on handling the finished medicine products and raw materials for medicine production of Ranbaxy Company
To:
- Departments of Health of provinces and central-affiliated cities;
- National Institute of Drug Quality Control;
- Institute of Drug Quality Control of Ho Chi Minh city;  
- Medicine importers and producers;
- Representative office of Ranbaxy Laboratories Ltd., in Vietnam.
- Pursuant to current pharmaceutical regulations of Vietnam;
- Pursuant to notices of Food and Drug Administration of United States (US-FDA) forbidding several establishments of Ranbaxy Laboratories Ltd from producing and distributing medicines and raw materials for medicine production on American market:
+ Factory in Toansa, India – address: Village Toansa, P.O Rail Majra, Nawanshahar District - 144533 Punjab, India;
+ Factory in Mohali, India – address: Plot No. A-41 Industrial Area, Phase VIII-A, S.A.S Nagar, Mohali - 160071 Pujab, India;
+ Factory in Paonta Sahib, India – address: Village Ganguwala, Tehsil Paonta Sahib, Sirmour - 173025, Himachal Pradesh, India;
+ Factory in Batamandi, India – address: Village Batamandi, Tehsil Paonta Sahib - 173025, Himachal Pradesh, India;
+ Factory in Dewas, India – address: Industrial Area 3, A B Road, Dewas - 455001 Madhya Pradesh, India;
+ Ohm Laboratories in Gloversville , USA;
- According to the report dated 13/3/2013 of representative office of Ranbaxy Laboratories Ltd., in Vietnam;
To ensure the safety for users, the Drug Administration of Vietnam notifies that: